Introduction
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) can be caused by activating mutations or rearrangements of the rearranged during transfection (RET) gene.
MTC originates from the calcitonin-producing C cells of the thyroid and can occur sporadically (75%) or as part of a familial cancer syndrome (25%). The latter occurs as multiple endocrine neoplasia (MEN) type 2 syndrome (MEN2A and MEN2B) or as familial MTC. [1] [2] [3] PTC is the most common thyroid cancer (80% of all thyroid cancers) and originates from the follicular epithelial cells of the thyroid. In 2.5%-40% of PTC, a RET rearrangement is found, although this percentage is higher in patients exposed to radiation. 1 Total thyroidectomy and extensive lymph node dissection is the curative treatment for MTC and PTC, followed by radioiodine ablation in PTC. However, recurrent disease is often seen in sporadic MTC, and until recently, reoperation was the only therapeutic option. In iodine-refractory PTC, no effective adjuvant therapy is available as well. 4, 5 New systemic therapies are therefore needed for both recurrent MTC and PTC.
With RET being the gene involved in a subset of MTC and PTC, it is logical to consider the encoded receptor as an important target for systemic therapy. RET is expressed in all tumour cells and continuous autophosphorylation on its tyrosine kinase (TK) residues caused by mutations (MEN2) or rearrangements (PTC) on RET results in a constant activation of downstream signalling pathways that ultimately lead to tumour growth. 1 Therefore, inhibition of RET phosphorylation and its downstream pathways could be of great value.
Small-molecule inhibitors that selectively inhibit TK have been proven to be effective in the treatment of several neoplastic diseases. [6] [7] [8] A number of these clinically useful inhibitors target TK receptors that belong to the same family group of proteins as RET. 9 Several TK inhibitors have already been tested in vitro and evaluated in phase II clinical trials (Table 1) .
In a large number of patients (25%-81%), a stable disease state can be established, and some patients even show a partial response (2%-33%). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Because most studies have focused on one particular TK inhibitor and have not looked for mutation specificity, it is hard to compare these compounds for the different patient groups.
We therefore set out to compare the efficiency of four recently developed TK inhibitors, XL184 (cabozantinib), vandetanib, sunitinib, and axitinib, using three cell lines: MTC-TT reported to be derived from a sporadic MTC expressing a C634W RET mutation, MZ-CRC-1 derived from a patient with metastatic sporadic MTC expressing an M918T RET mutation, and TPC-1 derived from a patient with PTC expressing a RET/PTC-1 rearrangement. 
Materials and Methods

Cell culture
MZ-CRC-1, MTC-TT, TPC-1, and HEK293 (human embryonic kidney cells) cell lines were cultured as described in Supplemental Materials and Methods. Control cells were grown without DMSO or TK inhibitor. Proliferation was measured at 1, 4, and 7 d using a cell proliferation kit (MTT assay; Roche, Almere, The Netherlands) according to the manufacturer's instructions. The concentration that led to 50% growth inhibition (IC50) was determined using linear interpolation at r=0.5 (Supplemental Table 1 ). If IC50
concentrations were between 0.5 and 5 µM, additional cell proliferation assays were performed (Supplemental Figure 1, A-D) . All experiments were performed in triplicate.
Cell lysates and Western blot analysis
MZ-CRC-1, MTC-TT, and TPC-1 cells were treated with 0, IC50, and maximal concentrations of the different TK inhibitors for 0, 2, and 5 d. Cell lysates were prepared as described in Supplemental Materials and Methods, and supernatants were stored at -80C before they were further processed for SDS-PAGE followed by Western blot analysis. The antibodies used are described in Supplemental Materials and Methods. All experiments were performed in duplicate.
RNA extraction and RT-PCR
MTC-TT and MZ-CRC-1 cells, treated with 0, IC50, and maximal concentrations (Supplemental Table 1 ) of XL184 and vandetanib, respectively, were collected after 0, 2, and 5 d. RNA extraction and RT-PCR procedures are described in the Supplemental Materials and
Methods.
Statistical analysis
The statistical analysis was performed using the software program SPSS version 16.0.
Results
Effect of different TK inhibitors on cell proliferation
A dose-dependent decrease in cell proliferations was seen for all four inhibitors ( Table 2 ).
Effect of XL184 and vandetanib on RET autophosphorylation
Inhibition of RET autophosphorylation on tyrosine 1062 was observed for the three cell lines tested after 2 d of treatment with XL184 (MTC-TT and TPC-1) and vandetanib (MZ-CRC-1).
However, only vandetanib was able to induce this effect with IC50 levels ( Figure 1D ). 
Effect of XL184 and vandetanib on RET downstream signalling pathways
RET is involved in the activation of several signalling pathways, including the MAPK pathway. 20 Therefore, we evaluated the effect of XL184 and vandetanib in ERK activation. 
Discussion
We compared the effects of four TK inhibitors, XL184, vandetanib, sunitinib, and axitinib, on cell proliferation and RET inhibition and looked for mutation specificity using cell lines harbouring a MEN2A mutation (MTC-TT), a MEN2B mutation (MZ-CRC-1), and a RET/PTC rearrangement (TPC-1). Our results showed that all four TK inhibitors are capable of reducing cell proliferation to some extent. However, XL184 was found to be the most efficient inhibitor for MEN2A and PTC-derived cell lines, whereas vandetanib proved to be the most potent inhibitor for MEN2B.
We also showed that XL184 and vandetanib were able to decrease RET autophosphorylation and expression levels in MTC-TT and MZ-CRC-1 cells, respectively.
However, only vandetanib exerted this effect by inhibiting RET transcription. It is possible that for XL184, lysosomal or proteasomal degradation is involved, as was described for other inhibitors. 20 For TPC-1 a marked decrease in RET phosphorylation levels was detected, but surprisingly, RET/PTC expression levels increased after exposure to XL184. This dual effect might be the result of a negative feedback mechanism to compensate a reduction in RET activation. Furthermore, it shows that XL184 exerts its effect in PTC by direct inhibition of RET autophosphorylation and that lysosomal or proteasomal degradation may not be effective due to the presence of the fusion protein.
Finally, we explored the effect of these drugs in a downstream signalling pathway directly activated by RET, the MAPK pathway. For MTC-TT and MZ-CRC-1, exposure to XL184
and vandetanib, respectively, induced a marked decrease in ERK phosphorylation.
Interestingly, a reduction on ERK expression was also observed for these cell lines, Because no TK inhibitor was superior for the cell lines tested, our in vitro results suggest that mutation-specific therapies could be beneficial for the treatment of MTC and PTC.
However, because only three different mutations were analysed, additional mutational studies are necessary to confirm this specificity.
To date, no distinction has been made between the different RET-related mutational subtypes (MEN2A/MEN2B/PTC) in clinical trials, and it is known that aspecific targeting of TK inhibitors can also contribute to antitumor effects. However, the risk of severe side effects for the patients in combination with the development of resistance to the TK inhibitors incorrectly used reinforces the need of mutation specific therapies. Furthermore, the combined use of different TK inhibitors for multiple targeting will also benefit from this knowledge, because only then optimal combinations of inhibitors can be chosen.
In conclusion, our results are in general agreement with the outcome of the clinical trials, supporting the idea that XL184 and vandetanib are two potent inhibitors for tumour response in MTC. We also showed that there is specificity of these inhibitors for the treatment of different RET mutations, which suggest that mutation-specific therapies will likely improve the outcome of ongoing studies. Thus, reanalysis of already performed trials based on mutation status is more than worthwhile.
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